1036761-96-2 Usage
Uses
Used in Pharmaceutical Research and Development:
N-Methyl-2-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetamide is used as a building block for the synthesis of various pharmaceutical compounds due to its unique chemical structure and potential biological activity. It is of interest to researchers in the pharmaceutical industry for its potential to contribute to the development of new drugs.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, N-Methyl-2-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetamide is employed for its potential therapeutic applications. Its structure allows for the exploration of its interactions with biological targets, which may lead to the discovery of new drugs with improved efficacy and safety profiles.
Used in Drug Synthesis:
N-Methyl-2-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetamide is used as a key intermediate in the synthesis of pharmaceutical compounds. Its boron-containing ring structure and methyl group provide opportunities for chemical modifications that can enhance the properties of the resulting drugs.
Used in Bioactivity Studies:
N-Methyl-2-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetamide is utilized in bioactivity studies to evaluate its potential as a therapeutic agent. Researchers investigate its interactions with biological systems to understand its mechanism of action and identify possible applications in treating various diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 1036761-96-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,6,7,6 and 1 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1036761-96:
(9*1)+(8*0)+(7*3)+(6*6)+(5*7)+(4*6)+(3*1)+(2*9)+(1*6)=152
152 % 10 = 2
So 1036761-96-2 is a valid CAS Registry Number.
1036761-96-2Relevant academic research and scientific papers
NEW COMPOUNDS
-
Page/Page column 107-108, (2008/12/06)
The invention relates to new bicyclic heterocyclic derivative compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
